endpts.com Open in urlscan Pro
143.204.215.22  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



Illustration: Shutterstock
July 19, 2023 11:14 AM EDT
Financing
Startups
Deals


BIOTECH’S OP­TI­MISM IS RE­TURN­ING AMID SIGNS OF A BET­TER SEC­OND HALF AND A
BRIGHTER 2024


KYLE LAHUCIK

ASSOCIATE EDITOR

Odysseus even­tu­al­ly made it to shore, as Bridge­Bio CEO Neil Ku­mar
re­mind­ed the in­dus­try last Fri­day in a nod to Homer’s clas­sic tale. And on
Mon­day, his biotech cel­e­brat­ed a key Phase III win, putting wind in its
sails for a trip to the FDA.

Biotechs every­where are hop­ing for a sim­i­lar mo­ment in the sun af­ter a
two-year trou­bled odyssey be­set by low rounds of pri­vate fi­nanc­ing,
mis­aligned val­u­a­tion ex­pec­ta­tions, a large­ly un­re­ward­ing pub­lic
mar­ket and a dearth of IPOs.


TO READ ENDPOINTS NEWS BECOME A FREE SUBSCRIBER

Unlock this article instantly, along with access to limited free monthly
articles and our suite of newsletters

SIGN UP LOG IN


MORE LIKE THIS

 * Lon­za cites biotech fund­ing slow­down as it low­ers sales out­look for the
   year July 21, 2023
 * Part­nered with Lil­ly, TVM Cap­i­tal and Tillotts fund oral in­flam­ma­to­ry
   bow­el dis­ease drug with up to $28M July 21, 2023
 * Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for
   $125M small mol­e­cule pact with Re­cludix July 20, 2023


TRENDING NOW


AF­TER SEV­EN PA­TIENT DEATHS, ADC GETS PAR­TIAL HOLD AND DE­CIDES TO STOP
ZYN­LON­TA TRI­AL


SCOOP: CNS BIOTECH MAP­LIGHT THER­A­PEU­TICS EYES $175M RAISE FOR PHII
CLIN­I­CAL TRI­ALS IN SCHIZ­O­PHRE­NIA, AUTISM AND ...


PAS­SAGE BIO LAYS OFF 26% OF STAFF, LETS TWO EX­EC­U­TIVES GO A YEAR AF­TER
DOWN­SIZ­ING, LEAD­ER­SHIP SHUF­FLE


'WE SIM­PLY CAN­NOT SUS­TAIN': IDOR­SIA WEIGHS LAY­OFFS, DEALS, PIPELINE TRIMS
TO BRING COST DOWN


TURN­STONE BI­O­LOG­ICS RIDES BIOTECH'S IPO TRAIN IN FRI­DAY DE­BUT


GRAIL PUSHED A MORE RE­STRIC­TIVE EM­PLOY­EE AR­BI­TRA­TION AGREE­MENT SHORT­LY
BE­FORE LAW­SUITS

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


E-MAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET


ABOUT YOU







SUBSCRIPTIONS

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET


INSTANT SIGN UP